201 related articles for article (PubMed ID: 32902184)
21. First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non-Small-Cell Lung Cancer.
Remick JS; Schonewolf C; Gabriel P; Doucette A; Levin WP; Kucharczuk JC; Singhal S; Pechet TTV; Rengan R; Simone CB; Berman AT
Clin Lung Cancer; 2017 Jul; 18(4):364-371. PubMed ID: 28162946
[TBL] [Abstract][Full Text] [Related]
22. Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers.
Ding XP; Zhang J; Li BS; Li HS; Wang ZT; Yi Y; Sun HF; Wang DQ
Asian Pac J Cancer Prev; 2012; 13(1):319-23. PubMed ID: 22502693
[TBL] [Abstract][Full Text] [Related]
23. Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer.
Abe T; Iino M; Saito S; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
J Radiat Res; 2021 Sep; 62(5):894-900. PubMed ID: 34260719
[TBL] [Abstract][Full Text] [Related]
24. Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer.
Zhou L; Liu J; Xue J; Xu Y; Gong Y; Deng L; Wang S; Zhong R; Ding Z; Lu Y
Radiat Oncol; 2014 May; 9():117. PubMed ID: 24884773
[TBL] [Abstract][Full Text] [Related]
25. Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study.
Martinussen HM; Reymen B; Wanders R; Troost EG; Dingemans AC; Öllers M; Houben R; De Ruysscher D; Lambin P; van Baardwijk A
Radiother Oncol; 2016 Nov; 121(2):322-327. PubMed ID: 27884510
[TBL] [Abstract][Full Text] [Related]
26. Survival and Toxicity of Hypofractionated Intensity Modulated Radiation Therapy in 4 Gy Fractions for Unresectable Stage III Non-Small Cell Lung Cancer.
Kong C; Zhu X; Shi M; Wang L; Chen C; Tao H; Jiang N; Yan P; Zhao L; Song X; He X
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):710-719. PubMed ID: 32275994
[TBL] [Abstract][Full Text] [Related]
27. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.
Jiang ZQ; Yang K; Komaki R; Wei X; Tucker SL; Zhuang Y; Martel MK; Vedam S; Balter P; Zhu G; Gomez D; Lu C; Mohan R; Cox JD; Liao Z
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):332-9. PubMed ID: 22079735
[TBL] [Abstract][Full Text] [Related]
28. Positron emission tomography for staging locally advanced cervical cancer and assessing intensity modulated radiotherapy approach.
Draghini L; Costantini S; Vicenzi L; Italiani M; Loreti F; Trippa F; Arcidiacono F; Casale M; Mantello G; Maranzano E
Radiol Med; 2019 Sep; 124(9):819-825. PubMed ID: 30904982
[TBL] [Abstract][Full Text] [Related]
29. Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial?
Meng Y; Luo W; Xu H; Wang W; Zhou S; Tang X; Li Z; Zhou C; Yang H
Radiother Oncol; 2021 May; 158():118-124. PubMed ID: 33636232
[TBL] [Abstract][Full Text] [Related]
30. Feasibility of omitting the clinical target volume under PET-CT guidance in unresectable stage III non-small-cell lung cancer: A phase II clinical trial.
Cui T; Zhang A; Cui J; Chen L; Chen G; Dai H; Qin X; Li G; Sun J
Radiother Oncol; 2023 Apr; 181():109505. PubMed ID: 36764460
[TBL] [Abstract][Full Text] [Related]
31. Selective mediastinal node irradiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E(B)US-NA information in addition to PET-CT for delineation?
Peeters ST; Dooms C; Van Baardwijk A; Dingemans AM; Martinussen H; Vansteenkiste J; Decaluwé H; De Leyn P; Yserbyt J; Nackaerts K; De Wever W; Deroose CM; De Ruysscher D
Radiother Oncol; 2016 Aug; 120(2):273-8. PubMed ID: 27291644
[TBL] [Abstract][Full Text] [Related]
32. Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era.
Vargo JA; Kim H; Choi S; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Comerci JT; Beriwal S
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1091-8. PubMed ID: 25303889
[TBL] [Abstract][Full Text] [Related]
33. Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy.
Lazzari R; Riva G; Augugliaro M; Vavassori A; Dicuonzo S; Cattani F; Comi S; Colombo N; Jereczek-Fossa BA
Int J Gynecol Cancer; 2020 May; 30(5):607-612. PubMed ID: 32188626
[TBL] [Abstract][Full Text] [Related]
34. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ
J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394
[TBL] [Abstract][Full Text] [Related]
35. Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial.
Askoxylakis V; Dinkel J; Eichinger M; Stieltjes B; Sommer G; Strauss LG; Dimitrakopoulou-Strauss A; Kopp-Schneider A; Haberkorn U; Huber PE; Bischof M; Debus J; Thieke C
Radiat Oncol; 2012 Sep; 7():157. PubMed ID: 22974533
[TBL] [Abstract][Full Text] [Related]
36. Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer.
Guckenberger M; Kavanagh A; Partridge M
Strahlenther Onkol; 2012 Oct; 188(10):894-900. PubMed ID: 22933031
[TBL] [Abstract][Full Text] [Related]
37. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.
Vanuytsel LJ; Vansteenkiste JF; Stroobants SG; De Leyn PR; De Wever W; Verbeken EK; Gatti GG; Huyskens DP; Kutcher GJ
Radiother Oncol; 2000 Jun; 55(3):317-24. PubMed ID: 10869746
[TBL] [Abstract][Full Text] [Related]
38. Use of simultaneous radiation boost achieves high treatment response rate in patients with metastatic gastric cancer.
Yang J; Liu J; Gao S; Yang Y; Kong W; Ren W; Zhu L; Yang M; Wei J; Zou Z; Qian X; Liu B; Yan J
J Cancer Res Ther; 2018 Jan; 14(1):36-39. PubMed ID: 29516956
[TBL] [Abstract][Full Text] [Related]
39. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results.
King SC; Acker JC; Kussin PS; Marks LB; Weeks KJ; Leopold KA
Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):593-9. PubMed ID: 8948343
[TBL] [Abstract][Full Text] [Related]
40. High dose simultaneous integrated boost for node positive cervical cancer.
Jayatilakebanda I; Tsang YM; Hoskin P
Radiat Oncol; 2021 May; 16(1):92. PubMed ID: 34001158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
